1h Free Analyst Time
Calcitonin Gene Related Peptide (CGRP) - Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury. CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception. Speak directly to the analyst to clarify any post sales queries you may have.
Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Preclinical and Discovery stages are 1, 1, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology and Oncology which include indications Migraine, Cluster Headache Syndrome (Cluster Headache), Dental Pain (Toothache/Tooth Pain), Inflammatory Pain, Medullary Thyroid Cancer, Osteoarthritis Pain and Psoriasis.
The latest report Calcitonin Gene Related Peptide - Drugs In Development, 2022, outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP) Calcitonin Gene Related Peptide (CGRP)
- The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- REPORT COVERAGE
- Calcitonin Gene Related Peptide (CGRP) - Overview
- Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
- Acherx LLC
- AfaSci Inc
- Eli Lilly and Co
- H. Lundbeck AS
- Kissei Pharmaceutical Co Ltd
- Nepsone ehf
- Pharmnovo AB
- Shandong Boan Biotechnology Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Teva Pharmaceutical Industries Ltd
- Vaxxinity Inc
- Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
- ACX-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AFAP-3 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- eptinezumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- fremanezumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- galcanezumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Gene Therapy to Inhibit CGRP for Medullary Thyroid Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- JS-010 - Drug Profile
- Product Description
- Mechanism Of Action
- KCZ-1279 - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibody to Inhibit CGRP for Migraine - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit CGRP for Psoriasis - Drug Profile
- Product Description
- Mechanism Of Action
- UB-313 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Calcitonin Gene Related Peptide (CGRP) - Dormant Products
- Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
- Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones
- Featured News & Press Releases
- Jun 24, 2022: Teva announces promising interim results from its study PEARL, about the impact of AJOVY (fremanezumab)
- Jun 16, 2022: Results from the DELIVER study with Vyepti has been published in a top-ranking medical journal
- Jun 15, 2022: Otsuka obtains approval in Japan for Auto-Injector dosage form for AJOVY subcutaneous injection 225 mg for preventive treatment of migraine
- Jun 09, 2022: Lundbeck to present data on VYEPTI (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, furthering clinical and real-world evidence for migraine prevention
- Jun 09, 2022: Teva to present latest data on AJOVY (fremanezumab-vfrm) injection at the 2022 American Headache Society Annual Meeting
- Jun 09, 2022: New real-world data evaluating AJOVY (fremanezumab-vfrm) injection use in patients with migraine presented at 2022 American Headache Society Annual Meeting
- May 17, 2022: Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s AJOVY (fremanezumab), for the preventive treatment of migraine in adults
- Apr 02, 2022: Lundbeck to present new data at AAN 2022 adding to clinical evidence regarding VYEPTI
- Apr 01, 2022: Teva to present new analyses of AJOVY (fremanezumab-vfrm) injection and AUSTEDO (deutetrabenazine) tablets at 2022 American Academy of Neurology Annual Meeting
- Mar 02, 2022: Teva Canada welcomes public drug plan reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the Non-Insured Health Benefits Program for Patients prescribed AJOVY (fremanezumab) for the preventive treatment of migraine in adults
- Jan 24, 2022: Vyepti (eptinezumab) approved by the EU Commission for the preventive treatment of migraine in adults
- Nov 19, 2021: Lilly begins enrolment in Phase IV trial of Emgality for migraine prevention
- Nov 12, 2021: Vyepti recommended for approval in the EU by CHMP for the preventive treatment of migraine in adults
- Nov 08, 2021: From clinical trial efficacy to real-world effectiveness first AJOVY (fremanezumab) data from European Real World Evidence Program
- Nov 01, 2021: Lundbeck reports positive results for Vyepti(eptinezumab) from the DELIVER study in patients with migraine and prior preventive treatment failures
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Acherx LLC, 2022
- Pipeline by AfaSci Inc, 2022
- Pipeline by Eli Lilly and Co, 2022
- Pipeline by H. Lundbeck AS, 2022
- Pipeline by Kissei Pharmaceutical Co Ltd, 2022
- Pipeline by Nepsone ehf, 2022
- Pipeline by Pharmnovo AB, 2022
- Pipeline by Shandong Boan Biotechnology Co Ltd, 2022
- Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Pipeline by Teva Pharmaceutical Industries Ltd, 2022
- Pipeline by Vaxxinity Inc, 2022
- Dormant Projects, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acherx LLC
- AfaSci Inc
- Eli Lilly and Co
- H. Lundbeck AS
- Kissei Pharmaceutical Co Ltd
- Nepsone ehf
- Pharmnovo AB
- Shandong Boan Biotechnology Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Teva Pharmaceutical Industries Ltd
- Vaxxinity Inc
